Novel and sensitive ELISA for the rapid quantification of recombinant p64K protein

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 3, 2011, Pages 403-408

  Leyva, Alberto ^a   Sánchez, Julio C ^a   Álvarez, Denis ^a   Pérez, Bárbara ^a   López, Lissette ^a   Paz, Shaily ^a   Torres, Edel ^a   González, Tatiana ^a   Font, Milagros ^a   Hernández, Neyda ^a   Valdés, Rodolfo ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Conjugated vaccine; ELISA; Manufacturing process; P64k r; Validation

Indexed keywords

BACTERIAL PROTEIN; PROTEIN P64K; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ARTICLE; BIOASSAY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LIMIT OF QUANTITATION; MOLECULAR INTERACTION; NEISSERIA MENINGITIDIS; NONHUMAN; PARAMETERS OF MEASUREMENT AND ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; VALIDATION STUDY;

ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; LIMIT OF DETECTION; NEISSERIA MENINGITIDIS; PROTEIN STABILITY; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 79953220131     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.01.041     Document Type: Article

References (29)

1. R. Silva, M. Selman, G. Guillen, L. Herrera, J.R. Fernández, L.I. Novoa, J. Morales, S. González, B. Tamargo, J. del Valle, et al., Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and its use in vaccine preparations, Eur. Patent Appl. 0474313A2, U.S. Pat. 5 286484, 1992.
2. Bringas R., Fernandez J.R. A lipoamide dehydrogenase from Neisseria meningitidis has a lipoyl domain. Protein. Struct. Funct. Genet. 1995, 21:303-306.
3. Musacchio A., Gonzalez S., Caballero E., HØiby E.A., Rosenquist E. Antibody response against the 64kDa protein from Neisseria meningitidis after systemic meningococcal disease, and after vaccination with two different serogroup B meningococcal vaccines among young adults in Iceland. Proceedings of the Ninth International Pathogenic Neisseria Conference 1994, pp. 460. J.S. Evans, S.E. Post, M.C.J. Maiden, I.M. Feavers (Eds.).
4. Guillen G., Alvarez A., Silva R., Morera V., Gonzalez S., Carmenate T., Gonzalez L.J., Estrada R., Támbara Y., Padron G. Expression in Escherichia coli of the lpdA gene; protein sequence analysis and immunological characterization of the P64k protein from Neisseria meningitidis, L. Herrera. Biotechnol. Appl. Biochem. 1998, 27:189-196.
5. Espinosa R., Caballero E., Musacchio A., Silva R. Production of a recombinant, immunogenic protein, P64k, of Neisseria meningitidis in Escherichia coli in fed-batch fermentes. Biotechnol. Lett. 2002, 24:343-346.
6. Alvarez-Lajonchere L., Martínez G., Morales J., Aguilar J.C., Dueñas S. Immunization with HCV synthetic peptides conjugated to the P64k protein elicited strong antibody response in mice. Biotecnol. Apl. 2003, 20:209-213. (Cuba's Journal).
7. Pérez A.E., Dickinson F.O., Banderas F., Serrano T., Llanes R., Guzmán D., Díaz P., Alvarez A., Guirola M., Caballero E., Canaan-Haden L., Guillén G. Safety and preliminary immunogenicity ofMenC/P64k, a meningococcal serogroupC conjugate vaccine with a new recombinant carrier, FEMS. Immunol. Med. Microbiol. 2006, 46:386-392.
8. Hermida L., Rodríguez R., Lazo L., Silva R., Zulueta A., Chinea G., López C., Guzmán M.G., Guillén G. A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods 2004, 115:41-49.
9. Garcia B., Neninger E., de la Torre A., Leonard I., Martinez R., Viada C., et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin. Cancer Res. 2008, 14:840-846.
10. González G., Crombet T., Catalá M., Mirabal V., Hernandez J.C., Gonzalez Y., Marinillo P., Guillen G., Lage A. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 1998, 9:1-5.
11. de la Sierra I.L., Pernot L., Proge T., Soludjian P., Shiltz M., Fourne R., Padron G. Molecular structure of the lipoamide dehydrogenase domain of a surface antigen from Neisseria meningitidis. J. Mol. Biol. 1997, 269:129-141.
12. Nazabal C., Carmenate T., Cruz S., Gonzalez S., Silva R., Musacchio A., Delgado M., Chinea G. Mapping of monoclonal antibodies specific to P64k: a common antigen of several isolates of Neisseria meningitidis. Can. J. Microbiol. 2001, 47:158-164.
13. Gonzalez S., Viña l., Nazabal C., Cinea G., Caballero E., Musacchio A. B-cell epitope mapping of the Neisseria meningitidis P64k protein using overlapping peptides. Biotechnol. Appl. Biochem. 2000, 32:1-8.
14. Geng D., Shankar G., Schantz A., Rajadhyaksha M., Davis H., Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J. Pharm. Biomed. Anal. 2005, 39:364-373.
15. Leyva A., Sánchez J.C., Valdes R., Font M., López L., Hernández N., Ferro W., Medina Y. A combinatorial strategy of a new monoclonal ELISA and immunoaffinity chromatography using sodium deoxycholate to increase the recovery of multimeric proteins like r-HBsAg. Talanta 2010, 81:314-319.
16. ICH. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Text on validation of analytical procedure: Text and methodology 2005, Q2 (R1), p. 1-13.
17. U.S.Food and Drug Administration Guidelines on General Principles of Process Validation 1998, March.
18. International Conference on the Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Q2A: Validation of Analytical Methods (Definitions and Terminology) (October 1994).
19. Sharp J.R. The problems of process validation. Pharm. J. 1986, 1:46-55.
20. L.I. Novoa, J.A. Machado, J.R. Fernandez, J. Benitez, R.E. Narciandi, J.L. Rodríguez, M.P. Estrada, J. García, L.S. Herrera, Methods for the expression of heterologous proteins produced in fuse form in E. coli, use thereof, expression vector and recombinants strains. European. Patent. Application EP416673, 1991.
21. Ey P.L., Prowse S.J., Jenkin C.R. Isolation of pure IgG1, IgG2a, IgG2b, immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 1978, 15:429-436.
22. Nakane P.K, Kawoi A. Peroxidase-labeled antibody a new method of conjugation. J. Histochem. Cytochem. 1974, 22:1084-1091.
23. Shap V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I., McKay G., Miller J.K., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., Yacobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 2000, 17:1551-1557.
24. Zor T., Selinge Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal. Biochem. 1996, 236:302-308.
25. Laemmli U.K. Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature 1970, 227:680-685.
26. Šeatović S., Inić-Kanada A., Stojanović M., Živković I., Jankov R.M., Dimitrijević L. Development of sandwich enzyme-linked immunosorbent assay for determination of tetanus toxoid concentration. J. Immunol. Immunochem. 2005, 1:31-44. http://www.informaworld.com/smpp/title~db=all~content=t713597271~tab=issueslist~branches=25-v2525.
27. Sakamoto S., Putalun W., Tsuchihashi R., Morimoto S., Kinjo J., Tanaka H. Development of an enzyme-linked immunosorbent assay (ELISA) using highly-specific monoclonal antibodies against plumbagin. Anal. Chim. Acta. 2008, 607:100-105.
28. Wood W.G. Matrix effects in immunoassays. Scand. J. Clin. Lab. Invest. Suppl. 1991, 205:105-112.
29. Lindholm J., Johansson M., Fornstedt T. Guidelines for analytical method development and validation of biotechnological synthesis of drugs.Production of a hydroxyprogesterone as model. J. Chromatogr B. 2003, 791:323-336.